<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01679340</url>
  </required_header>
  <id_info>
    <org_study_id>SOXSP</org_study_id>
    <nct_id>NCT01679340</nct_id>
  </id_info>
  <brief_title>A PhaseⅡ Study: SOX vs SP in Adjuvant Chemotherapy After D2 Surgery</brief_title>
  <official_title>Phase Ⅱ Study of S-1 Combined With Oxaliplatin (SOX)Verse S-1 Combined With Cisplatin(SP) in Adjuvant Chemotherapy After D2 Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Taiho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the efficiency and safety of SOX or SP adjuvant chemotherapy to phase II and&#xD;
      III gastric cancer patients after D2 surgery. If SOX is equal to SP in efficiency and less&#xD;
      toxicity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>replase free survival</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>S-1+oxaliplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-1: 80mg/m2, 3weeks/cycle(take for 14d, rest for 7d oxaliplatin: 65mg/m2, D1,D8, 3weeks/cycle after 6 cycles, then mono S-1 for 2-4 cycles, total 8-10 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S-1+cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>S-1: 80mg/m2, 3weeks/cycle(take for 14d, rest for 7d) cisplatin: 75mg/m2, D1, every 3 weeks After 6 cycles, then mono S-1 for 2-4 cycles, total 8-10 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>Mode of administration: orally (capsules) Dosing schedule:80mg/m2, Bid,D1-14,every 3 week,for 8-10cycles</description>
    <arm_group_label>S-1+cisplatin</arm_group_label>
    <arm_group_label>S-1+oxaliplatin</arm_group_label>
    <other_name>TS-1</other_name>
    <other_name>Aisiwan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>Mode of administration: intravenously Doseing schedule: 65 mg/m2 D1,D8,every 3 week, for 6 cycles</description>
    <arm_group_label>S-1+oxaliplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Mode of administration: intravenously Dosing schedule: 75mg/m2 D1,every 3 week,for 6 cycle</description>
    <arm_group_label>S-1+cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histologically confirmed Phase III adenocarcinoma of gastric and esophageal-gastric&#xD;
             junction ( AJCC 7th)&#xD;
&#xD;
          -  without previous treatment, including radiotherapy, chemotherapy and immunotherapy&#xD;
&#xD;
          -  Hb≥90g/L,WBC 4×109/L-10×109/L,ANC≥2×109/L,Platelet≥100×109/L&#xD;
&#xD;
          -  creatinine≤1 UNL&#xD;
&#xD;
          -  total bilirubin≤1.5 UNL,AST(SGOT),ALT(SGPT) and ALP≤2.5 UNL&#xD;
&#xD;
          -  ECOG score 0 - 2&#xD;
&#xD;
          -  take chemotherapy for 8 weeks after surgery&#xD;
&#xD;
          -  older than 18 years&#xD;
&#xD;
          -  can be followed up, good compliance&#xD;
&#xD;
          -  can take medicine orally&#xD;
&#xD;
          -  having signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  combined disease lead to Life Expectancy less than 3 years&#xD;
&#xD;
          -  any evidence to show metastasis,including cancer cells in peritoneal fluid&#xD;
&#xD;
          -  inability to take oral medication for difficult to swallow, intestinal&#xD;
             obstruction，active intestinal blooding or perforation&#xD;
&#xD;
          -  previous treatment,including cytotoxic chemotherapy, radio chemotherapy or&#xD;
             immunotherapy ( except corticosteroid hormone）&#xD;
&#xD;
          -  operation within 4 weeks, or not recovered from last major operation&#xD;
&#xD;
          -  allergy with fluorouracil&#xD;
&#xD;
          -  allergy with Platinum or any composition in research drugs&#xD;
&#xD;
          -  uncontrollable seizure disorder，central nervous system disease or mental disorders,&#xD;
             and has clinical significance by judgement of researchers, or can influnce&#xD;
             understanding of informed consent or compliance to take orally drugs&#xD;
&#xD;
          -  in the past 12 months, has clinical significant heart disease(active),such as&#xD;
             symptomatic coronary heart disease, &gt; =Stage II congestive cardiac failure;congestive&#xD;
             heart failure as NYHA standard, or serious arrhythmias need take medicine( as Appendix&#xD;
             10th),or myocardical infarction.&#xD;
&#xD;
          -  pregnancy， lactation， women in child-bearing period and her spouses reject to take&#xD;
             effictive method to conraception&#xD;
&#xD;
          -  other previous malignancy within 5 years, except healed skin basal cell carcinoma and&#xD;
             carcinoma in cervix&#xD;
&#xD;
          -  peripheral neuropathy&gt; grade 1 of CTCAEv3, except the neural abnormality patients who&#xD;
             only lose deep tendon reflex（DTRs）.&#xD;
&#xD;
          -  serious complicated infection or other complicated diseases and hard to controll.&#xD;
&#xD;
          -  As one of belowing:&#xD;
&#xD;
          -  ANC &lt; 2×109/L&#xD;
&#xD;
          -  Platelet&lt;100×109/L&#xD;
&#xD;
          -  total bilirubin&gt;1.5 UNL&#xD;
&#xD;
          -  ALAT、ASAT &gt; 2.5 x ULN&#xD;
&#xD;
          -  ALP&gt; 2.5 x ULN&#xD;
&#xD;
          -  Any investigational agent within the past 28 days. That is the patient had jioned&#xD;
             another trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shen Lin, professor</last_name>
    <phone>010-88196561</phone>
    <email>xiaotong10241@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shen Lin, Professor</last_name>
      <phone>010-88196561</phone>
      <email>xiaotong10241@sina.com</email>
    </contact>
    <investigator>
      <last_name>Shen Lin, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>June 13, 2012</study_first_submitted>
  <study_first_submitted_qc>September 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2012</study_first_posted>
  <last_update_submitted>May 17, 2015</last_update_submitted>
  <last_update_submitted_qc>May 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>Director of GI oncology</investigator_title>
  </responsible_party>
  <keyword>Gastric cancer</keyword>
  <keyword>D2 surgery</keyword>
  <keyword>S-1</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

